MNC Exodus Continues As Lilly India Head Sandeep Gupta Leaves For Glenmark Pharma
This article was originally published in PharmAsia News
Following a recent trend in emerging markets, Eli Lilly’s India Head shifts to Glenmark
You may also be interested in...
MUMBAI - As Pfizer Inc. warms up for an entry into the rapidly growing Indian insulin market, Eli Lilly & Co., which is already established in the Indian market, is looking to strengthen its franchise via a strategic collaboration with Lupin Ltd. - an Indian company making significant strides in the anti-diabetes, cardiology, nephrology and respiratory segments
Glenmark Steps Closer To First NCE With Positive Phase II Data For Crofelemer; Gears Up For Larger Trials
MUMBAI - Years of racing to put an original compound into the market looks set to be one step closer for India's Glenmark Pharmaceuticals as the company announced successful completion of Phase II multi-center clinical trials in India for its first-in-class anti-diarrheal agent crofelemer
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.